Merck's Glucophage® SR Receives Label Extension for Patients at High Risk of Type 2 Diabetes in the UK (2)

 

Merck's Glucophage® SR Receives Label Extension for Patients at High Risk of Type 2 Diabetes in the UK (2)

Publicado 17/05/2017 18:55:50CET

1) NICE guideline ph38: Type 2 diabetes: prevention in people at high risk. Published 12 July 2012. Available at: https://www.nice.org.uk/guidance/ph38/chapter/8-glossary#pre-diabetes 2) Diabetes UK. (2009). Preventing the Type 2 diabetes epidemic: October 2009. Available at: https://www.diabetes.org.uk/Documents/Reports/PrediabetesPreventingtheType2diabetesepidemicOct2009report.pdf 3) IDF (International Diabetes Federation). IDF Diabetes Atlas, seventh edition 2015. 4) ADA (American Diabetes Association). Standards of Medical Care in Diabetes. Diabetes Care 2013; 36(1):S11-66 5) ESC (European Society of Cardiology). Diabetes, Prediabetes and Cardiovascular Diseases. Available at: http://www.escardio.org/guidelines-surveys/esc-guidelines/Pages diabetes.aspx 6) Ryden L, Grant PJ, Anker SD et al. ESC Guidelines on diabetes, prediabetes, and cardiovascular diseases developed in collaboration with the EASD - Summary. Eur Heart J 2013; 34:3035-3087 7) IDF (International Diabetes Federation). (2012). Clinical Guidelines Task Force: Global guideline for the management of type 2 diabetes. 8) DPP Research Group. Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin. N Engl J Med 2002; 346:393-403 9) DPP Research Group. 10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. Lancet 2009; 374:1677-1686 10) Perreault L, Pan Q, Mather KJ et al. Effect of regression from prediabetes to normal glucose regulation on long-term reduction in diabetes risk: results from the Diabetes Prevention Program Outcomes Study. Lancet 2012; 379(9833):2243-2251 11) DPP Research Group. Long-term Effects of Lifestyle Intervention or Metformin on Diabetes Development and Microvascular Complications: the DPP Outcomes Study. The Lancet Diabetes and Endocrinology 2015 3(11):866-875

Contact: Bettina Frank +49-6151-72-4660

(Logo: http://mma.prnewswire.com/media/472778/Merck_Logo.jpg )

(Photo: http://mma.prnewswire.com/media/513155/Diabetes_UK.jpg )

Photo: http://mma.prnewswire.com/media/513155/Diabetes_UK.jpg http://mma.prnewswire.com/media/472778/Merck_Logo.jpg

Mejora la comunicación de tu empresa con Europa Press Comunicación

Mejora la comunicación de tu empresa con Europa Press Comunicación

La actualidad más visitada en EuropaPress logo: La actualidad más vista
Esta web utiliza cookies propias y de terceros para analizar su navegación y ofrecerle un servicio más personalizado y publicidad acorde a sus intereses. Continuar navegando implica la aceptación de nuestra política de cookies -
Uso de cookies